Cochrane Review Group
Epilepsy
77 systematic reviews in Epilepsy ask 970 questions. 19.6% have no studies to answer them, 13.9% rest on very low certainty evidence and 32.3% reach moderate or high certainty.
Reviews
77
Questions
970
current versions
No studies
19.6%
Moderate or high
32.3%
No studies 190 · 19.6%Ungraded 42 · 4.3%Very low 135 · 13.9%Low 289 · 29.8%Moderate 242 · 24.9%High 72 · 7.4%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Thinnest evidence
All no studies and very low questions| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Immunomodulatory interventions vs placebo Seizure freedom · people with focal epilepsy Immunomodulatory interventions for focal epilepsy (2023) · Cochrane | no estimate extracted | NR | No studies |
Immunomodulatory interventions vs placebo Allergic reactions · people with focal epilepsy Immunomodulatory interventions for focal epilepsy (2023) · Cochrane | no estimate extracted | NR | No studies |
Immunomodulatory interventions vs placebo Cognitive effects · people with focal epilepsy Immunomodulatory interventions for focal epilepsy (2023) · Cochrane | no estimate extracted | NR | No studies |
Immunomodulatory interventions vs placebo Quality of life · people with focal epilepsy Immunomodulatory interventions for focal epilepsy (2023) · Cochrane | no estimate extracted | NR | No studies |
Rapid vs slow withdrawal of antiepileptic drugs Seizure freedom after 1 year of AED withdrawal · people with epilepsy Rapid versus slow withdrawal of antiepileptic drugs (2022) · Cochrane | RR 0.76 [0.58, 1.01] | 1 study · 149 participants | Very low |
Rapid vs slow withdrawal of antiepileptic drugs Seizure freedom after 2 years of AED withdrawal · people with epilepsy Rapid versus slow withdrawal of antiepileptic drugs (2022) · Cochrane | RR 0.87 [0.58, 1.29] | 1 study · 149 participants | Very low |
Rapid vs slow withdrawal of antiepileptic drugs Seizure freedom after 5 years of AED withdrawal · people with epilepsy Rapid versus slow withdrawal of antiepileptic drugs (2022) · Cochrane | RR 1.4 [0.54, 3.65] | 1 study · 149 participants | Very low |
Intervention NR Primary outcomes · patients with stroke Antiepileptic drugs for the primary and secondary prevention of seizures after stroke (2022) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Secondary seizure prophylaxis after stroke · patients with stroke Antiepileptic drugs for the primary and secondary prevention of seizures after stroke (2022) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Secondary outcomes · patients with stroke Antiepileptic drugs for the primary and secondary prevention of seizures after stroke (2022) · Cochrane | no estimate extracted | NR | No studies |
Pregabalin vs placebo Adverse effect: headache · drug‐resistant focal epilepsy Pregabalin add‐on for drug‐resistant focal epilepsy (2022) · Cochrane | RR 0.65 [0.45, 0.94] | 6 studies · 1850 participants | Very low |
Pregabalin vs active comparators 50% or greater reduction in seizure frequency ‐ best‐case analysis · drug‐resistant focal epilepsy Pregabalin add‐on for drug‐resistant focal epilepsy (2022) · Cochrane | RR 1.6 [1.17, 2.19] | 3 studies · 1286 participants | Very low |
Reviews 77
Surgery for epilepsy
CochraneSoF table
8 questions
Topiramate versus carbamazepine monotherapy for epilepsy: an individual participant data review
CochraneSoF table
9 questions
Lamotrigine versus carbamazepine monotherapy for epilepsy: an individual participant data review
CochraneSoF table
7 questions
Sodium valproate versus phenytoin monotherapy for epilepsy: an individual participant data review
CochraneSoF table
9 questions
Carbamazepine versus phenobarbitone monotherapy for epilepsy: an individual participant data review
CochraneSoF table
9 questions
Drug management for acute tonic‐clonic convulsions including convulsive status epilepticus in children
CochraneSoF table
72 questions
Oxcarbazepine versus phenytoin monotherapy for epilepsy: an individual participant data review
CochraneSoF table
11 questions
Clobazam monotherapy for focal or generalized seizures
CochraneSoF table
12 questions
Yoga for epilepsy
CochraneSoF table
10 questions
Deep brain and cortical stimulation for epilepsy
CochraneSoF table
36 questions
Propofol versus thiopental sodium for the treatment of refractory status epilepticus
CochraneSoF table
3 questions
The role of high‐frequency oscillations in epilepsy surgery planning
CochraneSoF table
6 questions
Antiepileptic drugs for the treatment of infants with severe myoclonic epilepsy
CochraneSoF table
4 questions
Polyunsaturated fatty acid supplementation for drug‐resistant epilepsy
CochraneSoF table
6 questions
Early versus late antiepileptic drug withdrawal for people with epilepsy in remission
CochraneSoF table
3 questions
Corticosteroids including ACTH for childhood epilepsy other than epileptic spasms
CochraneSoF table
1 questions
Pharmacological interventions for epilepsy in people with intellectual disabilities
CochraneSoF table
5 questions
Non‐pharmacological interventions for people with epilepsy and intellectual disabilities
CochraneSoF table
1 questions
Vigabatrin versus carbamazepine monotherapy for epilepsy
CochraneSoF table
4 questions
Pharmacological treatments for preventing epilepsy following traumatic head injury
CochraneSoF table
15 questions
Neuropsychological and psychological interventions for people with newly diagnosed epilepsy
CochraneSoF table
2 questions
Anticonvulsant therapy for status epilepticus
CochraneSoF table
11 questions
Acupuncture for epilepsy
CochraneSoF table
36 questions
Psychological and behavioural treatments for adults with non‐epileptic attack disorder
CochraneSoF table
4 questions
Comparison of antiepileptic drugs, no treatment, or placebo for children with benign epilepsy with centro temporal spikes
CochraneSoF table
22 questions